References
1. Sulimov V.A., Golitsyn S.P., Panchenko E.P., et al. Diagnosis and treatment of atrial fibrillation. Recommendations of RKO, VNOA and ASSH. Moscow, 2012: 12 p. (in Russian)
2. Camm A.J., Kirchhof P, Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369–429.
3. Sanchez P.L., Fernandez-Aviles F. Structural heart disease: a new chapter in cardiovascular disease. ESC Monographic Issue: Structural Heart Disease. Ed. C.E. Ruiz. Eur Heart J. 2010; 12 (suppl E): e1.
4. Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373: 155–66.
5. Stewart S., Hart C.L., Hole D.J., McMurray J.J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002; 113: 359364.
6. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010; 31: 967–75.
7. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370–5.
8. Camm A.J., Lip G.Y.H., DeCaterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012; 31: 2369–429.
9. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857–67.
10. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention inanelderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet. 2007; 370: 493–503.
11. Connolly S.J., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events(ACTIVEW): a randomised controlled trial. Lancet. 2006; 367: 1903–12.
12. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin inpatients with atrial fibrillation. N Engl J Med. 2009; 361: 1139–51.
13. Patel M.R., Mahaffey K.W., Garg J., et al.; for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in non valvular atrial fibrillation. N Engl J Med. 2011; 365: 883–91.
14. Granger C.B., Alexander J.H., McMurray J.J., et al.; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981–92.
15. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347: 1825–33.
16. Van Gelder I.C., Groenveld H.F., Crijns H.J., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010; 362: 1363–73.